Herbal remedies in the United States: Potential adverse interactions with anticancer agents

Journal of Clinical Oncology

Volumn 22, Issue 12, 2004, Pages 2489-2503

  Sparreboom, Alex ^a   Cox, Michael C ^a   Acharya, Milin R ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CIMICIFUGA RACEMOSA EXTRACT; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; ECHINACEA EXTRACT; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCOPROTEIN P; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; KAVA EXTRACT; SABAL EXTRACT; SILYBUM MARIANUM EXTRACT; VALERIAN; PLANT MEDICINAL PRODUCT;

ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CIMICIFUGA RACEMOSA; DRUG RECEPTOR BINDING; ECHINACEA; EVENING PRIMROSE; GARLIC; GINKGO BILOBA; GINSENG; GRAPE; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; LIVER TOXICITY; MEDICAL LITERATURE; PRIORITY JOURNAL; REVIEW; SABAL; SILYBUM MARIANUM; SOYBEAN; DIET SUPPLEMENTATION; UNITED STATES;

ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; HERB-DRUG INTERACTIONS; HUMANS; PLANT PREPARATIONS; UNITED STATES;

EID: 2942729844     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.182     Document Type: Review

References (100)

1. Astin JA: Why patients use alternative medicine: Results of a national study. JAMA 279:1548-1553, 1998
2. Boon H, Stewart M, Kennard MA, et al: Use of complementary/alternative medicine by breast cancer survivors in Ontario: Prevalence and perceptions. J Clin Oncol 18:2515-2521, 2000
3. Jonas W: Alternative medicine: Learning from the past, examining the present, advancing to the future. JAMA 280:161-168, 1998
4. Johnson B: Prevention magazine assesses use of dietary supplements. HerbalGram 48:65, 2000
5. Klepser T, Doucette W, Horton H, et al: Assessment of a patient's perceptions and beliefs regarding herbal therapies. Pharmacotherapy 20:83-87, 2000
6. Eisenberg D, Davis R, Ettner S, et al: Trends in alternative medicine use in the United States. 1990-1997: Results of a follow-up national survey. JAMA 280:1569-1575, 1998
7. Kaufman D, Kelly J, Rosenberg L, et al: Recent patterns of medication use in the ambulatory adult population of the United States. JAMA 287:337-344, 2002
8. Richardson MA, Sanders T, Palmer JL, et al: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505-2514, 2000
9. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279:1200-1205, 1998
10. Zhou S, Gao Y, Jiang W, et al: Interactions of herbs with cytochrome P450. Drug Metab Rev 35:35-98, 2003
11. Hyodo I, Eguchi K, Nishina T, et al: Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: A nationwide survey in Japan. Cancer 97:2861-2868, 2003
12. Blumenthal M: Herbs continue slide in mainstream market: Sales down 14 percent. HerbalGram 58:71, 2003
13. DiGianni LM, Garber JE, Winer EP: Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 20:345-38S, 2002 (suppl 18)
14. Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: A systematic review. Cancer 83:777-782, 1998
15. Richardson MA, Straus SE: Complementary and alternative medicine: Opportunities and challenges for cancer management and research. Semin Oncol 29:531-545, 2002
16. Arkko PJ, Arkko BL, Kari-Koskinen O, et al: A survey of unproven cancer remedies and their users in an outpatient clinic for cancer therapy in Finland. Soc Sci Med [Med Psychol Med Sociol] 14A:511-514, 1980
17. Cassileth BR, Lusk EJ, Strouse TB, et al: Contemporary unorthodox treatments in cancer medicine: A study of patients, treatments, and practitioners. Ann Intern Med 101:105-112, 1984
18. Beaufort F, Drofenik M, Pleyer K: [Evaluation of drugs with questionable effectiveness and so-called natural preparations in oncology by patients. Results of a survey]. Wien Med Wochenschr 138:85-91, 1988
19. Morant R, Jungi WF, Koehli C, et al: [Why do cancer patients use alternative medicine?]. Schweiz Med Wochenschr 121:1029-1034, 1991
20. Liu JM, Chu HC, Chin YH, et al: Cross sectional study of use of alternative medicines in Chinese cancer patients. Jpn J Clin Oncol 27:37-41, 1997
21. VandeCreek L, Rogers E, Lester J: Use of alternative therapies among breast cancer outpatients compared with the general population. Altern Ther Health Med 5:71-76, 1999
22. Lee MM, Lin SS, Wrensch MR, et al: Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92:42-47, 2000
23. Morris KT, Johnson N, Homer L, et al: A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179:407-411, 2000
24. Ganz PA, Desmond KA, Leedham B, et al: Quality of life in long-term, disease-free survivors of breast cancer: A follow-up study. J Natl Cancer Inst 94:39-49, 2002
25. DiGianni LM, Kim HT, Emmons K, et al: Complementary medicine use among women enrolled in a genetic testing program. Cancer Epidemiol Biomarkers Prev 12:321-326, 2003
26. Nam RK, Fleshner N, Rakovitch E, et al: Prevalence and patterns of the use of complementary therapies among prostate cancer patients: An epidemiological analysis. J Urol 161:1521-1524, 1999
27. Kao GD, Devine P: Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 88:615-619, 2000
28. Lippert MC, McClain R, Boyd JC, et al: Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 86:2642-2648, 1999
29. Tesch BJ: Herbs commonly used by women: An evidence-based review. Am J Obstet Gynecol 188:544-55, 2003 (suppl 5)
30. Bernstein BJ, Grasso T: Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Huntingt) 15:1267-1272, 2001
31. Ioannides C: Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32:451-478, 2002
32. de Smet P: Herbal Remedies. N Engl J Med 347:2046-2056, 2002
33. Miller LG: Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158:2200-2211, 1998
34. Izzo AA, Ernst E: Interactions between herbal medicines and prescribed drugs: A systematic review. Drugs 61:2163-2175, 2001
35. Markman M: Safety issues in using complementary and alternative medicine. J Clin Oncol 20:39s-41s. 2002 (suppl 18)
36. Kivisto KT, Kroemer HK, Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions. Br J Clin Pharmacol 40:523-530, 1995
37. Lamba JK, Lin YS, Schuetz EG, et al: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54: 1271-1294, 2002
38. Sparreboom A, Nooter K: Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist Updat 3:357-363, 2000
39. Suzuki T, Nishio K, Tanabe S: The MRP family and anticancer drug metabolism. Curr Drug Metab 2:367-377, 2001
40. Ejendal KF, Hrycyna CA: Multidrug resistance and cancer: The role of the human ABC transporter ABCG2. Curr Protein Pept Sci 3:503-511, 2002
41. Kruijtzer CM, Beijnen JH, Schellens JHM: Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: An overview. Oncologist 7:516-530, 2002
42. Silgay C, Neil A: Garlic as a lipid lowering agent: A meta-analysis. J R Coll Physicians Lond 28:39-45, 1994
43. Warshafsky S, Kramer R, Sivak S: Effect of garlic on total serum cholesterol. Ann Intern Med 119:599-605, 1993
44. Berthold H: Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism. JAMA 279:1900-1902, 1998
45. Kiesewetter H, Jung F, Mrowietz C: Effects of garlic on blood fluidity and fibrinolytic activity: A randomized, placebo-controlled, double-blind study. Br J Clin Pract 44:24-29, 1990
46. Levi F, Pasche C, LaVecchia C, et al: Food groups and colorectal cancer risk. Br J Cancer 79:1283-1287, 1999
47. Lawson L, Ransom D, Hughes B: Inhibition of whole blood platelet aggregation by compounds in garlic clove extract and commercial garlic products. Thromb Res 65:141-156, 1992
48. Foster BC, Foster MS, Vandenhoek S, et al: An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4:176-184, 2001
49. Chen HW, Tsai CW, Yang JJ, et al: The combined effects of garlic oil and fish oil on the hepatic antioxidant and drug-metabolizing enzymes of rats. Br J Nutr 89:189-200, 2003
50. Brady JF, Ishizaki H, Fukuto JM, et al: Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem Res Toxicol 4:642-647, 1991
51. Brady JF, Li DC, Ishizaki H, et al: Effect of diallyl sulfide on rat liver microsomal nitrosamine metabolism and other monooxygenase activities. Cancer Res 48:5937-5940, 1988
52. Haber D, Siess M, De Waziers I, et al: Modification of hepatic drug-metabolizing enzymes in rats fed naturally occurring allyl sulphides. Xenobiotica 24:169-182, 1994
53. Kwak M, Kim S, Kwak J, et al: Inhibition of cytochrome P450 2E1 expression by organosulfur compounds allylsulfide, allylmercaptan and allylmethylsulfide in rats. Biochem Pharmacol 47:531-539, 1994
54. Kwak MK, Kim SG, Kim ND: Effects of garlic oil on rat hepatic P4502E1 expression. Xenobiotica 25:1021-1029, 1995
55. Reicks MM, Crankshaw DL: Modulation of rat hepatic cytochrome P-450 activity by garlic organosulfur compounds. Nutr Cancer 25:241-248, 1996
56. Guyonnet D, Belloirm C, Suschetet M, et al: Liver subcellular fractions from rats treated by organosulfur compounds from allium modulate mutagen activation. Mutat Res 466:17-26, 2000
57. Yang CS, Chhabra SK, Hong JY, et al: Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J Nutr 131:1041S-10455S, 2001
58. Jin L, Baillie TA: Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem Res Toxicol 10:318-327, 1997
59. Sheen LY, Chen HW, Kung YL, et al: Effects of garlic oil and its organosulfur compounds on the activities of hepatic drugmetabolizing and antioxidant enzymes in rats fed high- and low-fat diets. Nutr Cancer 35:160-166, 1999
60. Dalvi RR: Alterations in hepatic phase I and phase II biotransformation enzymes by garlic oil in rats. Toxicol Lett 60:299-305, 1992
61. Wu CC, Sheen LY, Chen HW, et al: Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem 50:378-383, 2002
62. Raucy JL: Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31: 533-539, 2003
63. Guyonnet D, Siess M, De Waziers I, et al: Modulation of phase II enzymes by organosulfur compounds from allium vegetables in rat tissues. Toxicol Appl Pharmacol 154:50-58, 1999
64. Wargovich M, Imada O, Stephen L: Initiation and post-initiation chemopreventitive effects of diallyl sulfide in esophageal carcinogenesis. Cancer Lett 64:39-42, 1992
65. Munday R, Mundsay C: Low doses of diallyl sulfide, a compound derived from garlic, increases tissue activities of quinone reductase and glutathione transferase in the gastrointestinal tract in the rat. Nutr Cancer 34:42-48, 1999
66. Gurley BJ, Gardner SF, Hubbard MA, et al: Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72:276-287, 2002
67. Gwilt PR, Lear CL, Tempero MA, et al: The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev 3:155-160, 1994
68. Markowitz JS, Devane CL, Chavin KD, et al: Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 74:170-177, 2003
69. Gallicano K, Foster B, Choudhri S: Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 55:199-202, 2003
70. Piscitelli SC, Burstein AH, Weiden N, et al: The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34:234-238, 2002
71. Fitzsimmons ME, Collins JM: Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P450 3A4: Potential contribution to high-risk first-pass metabolism. Drug Metab Dispos 25:256-266, 1997
72. Kim AE, Dintaman JM, Waddell DS, et al: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286:143-149, 1998
73. Ernst E: The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 136:42-53, 2002
74. DeFeudis FV, Drieu K: Ginkgo biloba extract (EGb 761) and CNS functions: Basic studies and clinical applications. Curr Drug Targets 1:25-58, 2000
75. Glisson J, Crawford R, Street S: The clinical applications of Ginkgo biloba, St. John's wort, saw palmetto, and soy. Nurse Pract 24:28-49, 1999
76. Solomon PR, Adams F, Silver A, et al: Ginkgo for memory enhancement: A randomized controlled trial. JAMA 288:835-840, 2002
77. Akiba S, Kawauchi T, Oka T, et al: Inhibitory effect of the leaf extract of Ginkgo biloba L. on oxidative stress-induced platelet aggregation. Biochem Mol Biol Int 46:1243-1248, 1998
78. Kudolo GB, Dorsey S, Blodgett J: Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. Thromb Res 108:151-160, 2002
79. Vaes LP, Chyka PA: Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: Nature of the evidence. Ann Pharmacother 34:1478-1482, 2000
80. Kalus P, Strik WK: [Phytotherapeutic drugs in psychiatry]. Ther Umsch 59:307-312, 2002
81. Dergal JM, Gold JL, Laxer DA, et al: Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging 19:879-886, 2002
82. Meisel C, Johne A, Roots I: Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis 167:367, 2003
83. Gopalakrishna R, Gundimeda U: Antioxidant regulation of protein kinase C in cancer prevention. J Nutr 132:3819S-3823S, 2002
84. Weiger W, Smith MR, Boon H, et al: Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 137:889-903, 2002
85. Shinozuka K, Umegaki K, Kubota Y, et al: Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci 70:2783-2792, 2002
86. Umegaki K, Saito K, Kubota Y, et al: Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats. Jpn J Pharmacol 90:345-351, 2002
87. Sun HF, Zuo Z, Yin OQ, et al: A "high-throughput" cocktail method for screening the effect of herbal product on liver isozyme activities: Experience with Ginkgo biloba. Clin Pharmacol Ther 71:P100, 2002 (abstr WPIII-91)
88. Zou L, Harkey MR, Henderson GL: Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71:1579-1589, 2002
89. He N, Edeki T: Effects of ginseng and Ginkgo biloba components on CYP3A4 mediated testosterone 6beta-hydroxylation in human liver microsomes. Clin Pharmacol Ther 73:P50, 2003 (abstr PII-81)
90. Duche JC, Barre J, Guinot P, et al: Effect of Ginkgo biloba on microsomal enzyme induction, Int J Clin Pharmacol Res 9:165-168, 1989
91. Mauro VF, Mauro LS, Kleshinski JF, et al: Impact of ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 10:247-251, 2003
92. Felber JP: [Effect of Ginkgo biloba on biological endocrine parameters]. Presse Med 15:1573-1674, 1986
93. Smith M, Lin KM, Zheng YP: An open trial of nifedipine-herb interactions: Nifedipine with St. John's wort, ginseng or Ginkgo biloba. Clin Pharmacol Ther 69:P86, 2001 (abstr Pill-89)
94. Yin OQ, Tomlinson B, Chow MS: Prediction and mechanism of herb-drug interaction: Effect of Ginkgo biloba on omeprazole in Chinese subjects. Clin Pharmacol Ther 73:P94, 2003 (abstr PDII-A-7)
95. He N, Edeki T: Effects of ginseng and Ginkgo biloba components on CYP2C9 mediated tolbutamide 4-methyl-hydroxylation in human liver microsomes. Clin Pharmacol Ther 71:P67, 2002 (abstr TPII-96)
96. Li CL, Wong YY: The bioavailability of ginkgolides in Ginkgo biloba extracts. Planta Med 63:563-565, 1997
97. Schinkel AH, Wagenaar E, van Deemter L, et al: Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705, 1995
98. Magnani B, Malini PL: Cardiac glycosides: Drug interactions of clinical significance. Drug Saf 12:97-109, 1995
99. Gilroy CM, Steiner JF, Byers T, et al: Echinacea and truth in labeling. Arch Intern Med 163:699-704, 2003
100. Bauer R, Wagner H: Echinacea species as potential immunostimulatory drugs, in Wagner H, Farnsworth N (eds): Economic and Medicinal Plant Research. Orlando, Fla, Academic Press, 1991, pp 253-322